Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oncology Institute (TOI) Payables (2020 - 2025)

Oncology Institute's Payables history spans 6 years, with the latest figure at $43.2 million for Q4 2025.

  • For Q4 2025, Payables rose 77.47% year-over-year to $43.2 million; the TTM value through Dec 2025 reached $43.2 million, up 77.47%, while the annual FY2025 figure was $43.2 million, 77.47% up from the prior year.
  • Payables reached $43.2 million in Q4 2025 per TOI's latest filing, up from $35.6 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $43.2 million in Q4 2025 to a low of $24707.0 in Q1 2021.
  • Average Payables over 5 years is $17.3 million, with a median of $14.2 million recorded in 2022.
  • Peak YoY movement for Payables: surged 72216.33% in 2021, then plummeted 39.76% in 2022.
  • A 5-year view of Payables shows it stood at $15.6 million in 2021, then plummeted by 39.76% to $9.4 million in 2022, then skyrocketed by 53.96% to $14.4 million in 2023, then surged by 68.58% to $24.3 million in 2024, then skyrocketed by 77.47% to $43.2 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Payables are $43.2 million (Q4 2025), $35.6 million (Q3 2025), and $34.9 million (Q2 2025).